BioCentury
ARTICLE | Clinical News

Exelon rivastigmine: Phase III data; marketed in EU

March 15, 1999 8:00 AM UTC

Researchers published data from a 725-patient trial in the British Medical Journal showing that patients receiving 12 mg/day of Exelon had a statistically significant improvement compared to placebo a...